Skip to content
HowShorted

Spyre Therapeutics, Inc. short interest in 2020

In 2020, Spyre Therapeutics, Inc.'s disclosed short interest ran from 0.72% of shares outstanding on 15 Jan 2020 to 3.85% on 31 Dec 2020, a change of +3.13 percentage points. The year's high was 6.81% on 15 Oct 2020 and its low 0.62% on 14 Feb 2020, averaging 3.03% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.22 days on 30 Nov 2020. Full history: Spyre Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Spyre Therapeutics, Inc. in 2020

2020 in figures

Start of year
0.72% (15 Jan 2020)
End of year
3.85% (31 Dec 2020)
Change
+3.13 pp
High
6.81% (15 Oct 2020)
Low
0.62% (14 Feb 2020)
Average
3.03%
Highest days to cover
24.22 (30 Nov 2020)
SEC filings marked
9

Every report in 2020

Spyre Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20200.72%6.19
31 Jan 20200.84%4.70
14 Feb 20200.62%3.76
28 Feb 20200.72%3.2610-K filed, results (8-K)
13 Mar 20201.01%4.74
31 Mar 20200.93%3.33
15 Apr 20200.81%3.11
30 Apr 20200.87%1.00results (8-K)
15 May 20200.82%1.6710-Q filed, results (8-K)
29 May 20201.42%2.95
15 Jun 20201.04%2.22
30 Jun 20202.55%1.79
15 Jul 20202.20%5.25
31 Jul 20203.13%9.11
14 Aug 20203.99%8.2010-Q filed, results (8-K)
31 Aug 20206.10%9.30
15 Sep 20205.99%8.78
30 Sep 20206.37%13.57
15 Oct 20206.81%9.08
30 Oct 20206.59%6.43
13 Nov 20205.81%17.4410-Q filed, results (8-K)
30 Nov 20205.85%24.22
15 Dec 20203.68%7.29
31 Dec 20203.85%9.84

See also: Spyre Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.